Presentation is loading. Please wait.

Presentation is loading. Please wait.

A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H

Published byKelly Johns Modified over 5 years ago

Similar presentations

Presentation on theme: "A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H"— Presentation transcript:

1 Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial 
A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H. Sicherer, MD, David M. Fleischer, MD, Amy M. Scurlock, MD, Brian P. Vickery, MD, Andrew H. Liu, MD, Alice K. Henning, MS, Robert Lindblad, MD, Peter Dawson, PhD, Marshall Plaut, MD, Hugh A. Sampson, MD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 5, Pages e3 (May 2015) DOI: /j.jaci Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Subject disposition.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 OFC results. Subjects were discontinued from treatment per protocol if they did not meet specific criteria at the year 2 OFC (OFC threshold ≥5000 mg or 10× baseline), and therefore the median values at year 3 are not presented. Blue stars indicate the group median at each time point. There was no statistically significant difference in medians between treatment groups. BL, Baseline. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Change from baseline in percentage of CD63+ basophils by 2-year response: all subjects. CPE, Crude peanut extract. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Peanut IgG4 levels by 2-year response for all subjects. *Subject-specific plots are shown, and blue stars indicate the group median at each time point. Repeated-measures analysis across all time points yielded a P value of .11, indicating that there was no statistically significant difference between 2-year responders compared with nonresponders. BL, Baseline. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E2 Peanut end point titration area under the curve by 2-year response for all subjects. *Subject-specific plots are shown, and blue stars indicate the group median at each time point. Repeated-measures analysis across time points through year 2 yielded a P value of .003, indicating there was a statistically significant decrease over time in 2-year responders compared with nonresponders. BL, Baseline. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.

Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Advances in Diagnosing Peanut Allergy

Advances in Diagnosing Peanut Allergy
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M

Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Advances in food allergy in 2015

Advances in food allergy in 2015
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,
Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study  John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study  John M. Brehm, MD, MPH, Brooke Schuemann, BS,
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

Similar presentations

Ads by Google